RxDoctor Payments Data

Jeffrey Wiencek

Family · Michigan City, INNPI 1174508840

Payments from drug & device makers

$478in general payments, 2019–2025

Across 20 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$142
  • Novo Nordisk$112
  • Novartis$53
  • Scpharmaceuticals Inc.$22
  • Lilly USA, LLC$22
  • AbbVie$21
  • plus $105 from 6 others

What the payments were for

  • Food & beverage$478100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$478 in reported general payments places this provider in the 50th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$53,559
Medicare patients
262
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$61,503
JanuviaSitagliptin Phosphate36$27,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,257
EliquisApixaban13$22,181
JardianceEmpagliflozin13$18,253
WegovySemaglutide11$15,007
EntrestoSacubitril/Valsartan13$11,006
FarxigaDapagliflozin Propanediol20$10,160
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$6,418
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,115
Albuterol Sulfate HfaAlbuterol Sulfate220$5,088
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,181
SymbicortBudesonide/Formoterol Fumarate15$3,518
Novolog FlexpenInsulin Aspart13$3,174
Atorvastatin Calcium333$1,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$112$76,51053 claims
MerckJanuvia$18$27,73836 claims
PfizerEliquis$16$22,18113 claims
Boehringer IngelheimJardiance$18$18,25313 claims
AstraZenecaFarxiga, Symbicort$142$13,67835 claims
NovartisEntresto$53$11,00613 claims
AbbVieSynthroid$21$83820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,392 family providers in Indiana.

Other family in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →